Eliminating racial/ethnic disparities in health and health care is a national priority, and obesity is a prime target. During the last 30 y in the United States, the prevalence of obesity among children has dramatically increased, sparing no age group. Obesity in childhood is associated with adverse cardio-metabolic outcomes such as hypertension, hyperlipidemia, and type II diabetes and with other long-term adverse outcomes, including both physical and psychosocial consequences. By the preschool years, racial/ethnic disparities in obesity prevalence are already present, suggesting that disparities in childhood obesity prevalence have their origins in the earliest stages of life. Several risk factors during pregnancy are associated with increased risk of offspring obesity, including excessive maternal gestational weight gain, gestational diabetes, smoking during pregnancy, antenatal depression, and biological stress. During infancy and early childhood, rapid infant weight gain, infant feeding practices, sleep duration, child's diet, physical activity, and sedentary practices are associated with the development of obesity. Studies have found substantial racial/ethnic differences in many of these early life risk factors for childhood obesity. It is possible that racial/ethnic differences in early life risk factors for obesity might contribute to the high prevalence of obesity among minority preschool-age children and beyond. Understanding these differences may help inform the design of clinical and public health interventions and policies to reduce the prevalence of childhood obesity and eliminate disparities among racial/ethnic minority children.

No abstract

Among US racial/ethnic minority women, we examined associations between maternal experiences of racial discrimination and child growth in the first 3 years of life. We analyzed data from Project Viva, a pre-birth cohort study. We restricted analyses to 539 mother-infant pairs; 294 were Black, 127 Hispanic, 110 Asian and 8 from additional racial/ethnic groups. During pregnancy, mothers completed the Experiences of Discrimination survey that measured lifetime experiences of racial discrimination in diverse domains. We categorized responses as 0, 1-2 or ≥3 domains. Main outcomes were birth weight for gestational age z-score; weight for age (WFA) z-score at 6 months of age; and at 3 years of age, body mass index (BMI) z-score. In multivariable analyses, we adjusted for maternal race/ethnicity, nativity, education, age, pre-pregnancy BMI, household income and child sex and age. Among this cohort of mostly (58.2%) US-born and economically non-impoverished mothers, 33% reported 0 domains of discrimination, 33% reported discrimination in 1-2 domains and 35% reported discrimination in ≥3 domains. Compared with children whose mothers reported no discrimination, those whose mothers reported ≥3 domains had lower birth weight for gestational age z-score (β -0.25; 95% CI: -0.45, -0.04), lower 6 month WFA z-score (β -0.34; 95% CI: -0.65, -0.03) and lower 3-year BMI z-score (β -0.33; 95% CI: -0.66, 0.00). In conclusion, we found that among this cohort of US racial/ethnic minority women, mothers' report of experiencing lifetime discrimination in ⩾ 3 domains was associated with lower fetal growth, weight at 6 months and 3-year BMI among their offspring.

No abstract

Heart failure is a global pandemic and there has been a growing effort to enroll patients from different geographical regions in randomized controlled trials. In this review, we examined regional variation in both patient characteristics and outcomes among several of the most recent global heart failure trials RECENT FINDINGS: Retrospective analyses of global heart failure trials have identified marked variations in both baseline characteristics and management of heart failure by region of enrollment. In some trials, this variation has been significant enough to cause differential treatment effects. We summarized key heterogeneity observed in global heart failure clinical trials. Differences in both patient population and organization of these trials abroad pose an important challenge in making interpretations and country-level decisions. As such, we encourage a concerted effort to account for these differences in future research.

No abstract

Introduction: Ventricular tachycardia (VT) is common in patients with end-stage heart failure, and pose additional risks in patients who have left ventricular assist devices (LVAD). We set out to examine if development of VT increases risk of mortality post-LVAD and the odds of developing right ventricular failure (RVF). Hypothesis: New onset VT increases both the risk of 1-year mortality post-LVAD and the odds of developing RVF. Methods: We performed a single-center retrospective analysis of 295 patients who received a continuous-flow durable LVAD (Heart-Mate II or HeartWare VAD) between Jan. 1 st 2006 through Dec. 31 st 2016. We stratified patients to 2 cohorts: those who had positive or negative history of VT pre-LVAD and those who developed VT post-LVAD. A survival analysis based on 1year survival was performed to find predictors of mortality and association with RVF. RVF severity was defined according to the new INTERMACS criteria. Results: In patients with and without a history of VT, 113 (67%) and 74 (58%) respectively developed VT post-LVAD. Baseline characteristics were similar among all cohorts (Table 1). Survival analysis demonstrated that both new onset VT ( Figure 1) and recurrence of VT did not increase the risk of 1 year mortality post-LVAD. Additionally, univariable analysis in patients without history of VT pre-LVAD showed that VT increased the odds of developing severe RVF (Table 2) (OR 6.20, p=0.020, 95%CI [1.33 -29.0]), but this was no longer significant in multivariable analysis. Conclusions: New onset and recurrent VT do not appear to be associated with increased mortality in LVAD patients. While there is a signal that new onset VT may increase the odds of severe RVF in patients without VT history pre-LVAD, this needs to be addressed prospectively and in larger cohorts.Introduction: Heart failure and obesity are two growing epidemics in the United States with significant overlap in patient populations. Morbid obesity is currently a relative contraindication to cardiac transplantation as previous data has shown decreased survival with extremes of body mass index (BMI). However, there is limited data that explores the relationship between BMI and adverse outcomes following left ventricular assist device (LVAD) implantation. This study aims to determine if there is an association between higher BMI and exchange-free survival at one year post LVAD implantation. Methods: This was a single-center, retrospective cohort study with patients who had undergone LVAD implantation at Barnes-Jewish Hospital between 2005 and 2018. Patients with age<18, BMI<18.5, or no available BMI information were excluded. Patients were divided into four groups: 18.5BMI<30 (BMI<30 group), 30BMI<35 (BMI 30-35 group), 35BMI<40 (BMI 35-40 group), and BMI 40 group. Subjects were censored for heart transplant. The groups were compared for death or LVAD exchange using the log-rank test. Results: We examined 734 patients who underwent LVAD implantation, including 574 HeartMate II devices (78%), 124 HeartWare HVAD devices (17%), ...

No abstract